Resolve Biosciences

Executive Summary

Resolve Biosciences is a German spatial biology company that has developed Molecular Cartography™, an end-to-end platform enabling multi-modal spatial profiling of RNA, protein, and morphology on the same tissue section with single-molecule sensitivity. Founded in 2018, the company targets precision medicine, particularly oncology and complex disease pathology, by providing researchers with a comprehensive tool to decode tissue microenvironments. The technology addresses a key bottleneck in spatial biology—simultaneous high-plex detection of biomolecules at subcellular resolution—positioning it as a potential leader in the rapidly growing spatial omics market. As a private entity, Resolve has not disclosed funding but likely relies on strategic partnerships, grants, or revenue from platform sales and service contracts. While the company faces competition from established players like 10x Genomics and NanoString, its unique approach to multi-modal integration may offer distinct advantages. Success will depend on commercial traction, validation through high-impact publications, and expansion into clinical diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of Molecular Cartography™ platform in key markets (e.g., US, EU)70% success
• Q4 2026Announcement of strategic partnership with major pharmaceutical company for oncology drug development50% success
• Q1 2027Publication of landmark study demonstrating clinical utility of platform in tumor microenvironment analysis80% success